Sandbox:MGS: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 1: Line 1:
__NOTOC__
[[Image:Small-cell-lung-cancer.jpg|400px|left|thumb| CT of SCLC showing extensive stage-Venous phase]]
{{Waldenström's macroglobulinemia}}
{{CMG}}{{AE}} {{MGS}}
 
{| style="border: 0px; font-size: 90%; margin: 3px; width: 800px"
|valign=top|
|+
! style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|Treatment Regimen}}
! style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|Drugs}}
! style="background: #4479BA; width: 300px;" | {{fontcolor|#FFF|Side effects}}
|-
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |
'''CHOP-R regimen'''
| style="padding: 5px 5px; background: #F5F5F5;" |
*Cyclophosphamide
*Doxorubicin
*Vincristine
*Prednisone
*Rituximab
| style="padding: 5px 5px; background: #F5F5F5;" |
*Nausea
*Alopecia
*Granulocytopenia
|-
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |
'''Ibrutinib'''
| style="padding: 5px 5px; background: #F5F5F5;" |
*Ibrutinib
| style="padding: 5px 5px; background: #F5F5F5;" |
*Fatigue
*Cytopenia
|-
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |
'''Rituximab'''
| style="padding: 5px 5px; background: #F5F5F5;" |
*Rituximab
| style="padding: 5px 5px; background: #F5F5F5;" |
*Infusion related reaction
*Infections
|-
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |
'''FR regimen'''
| style="padding: 5px 5px; background: #F5F5F5;" |
*Fludarabine
*Rituximab
| style="padding: 5px 5px; background: #F5F5F5;" |
*Neutropenia (63%)
*Thrombocytopenia
*Pneumonia
|-
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |
'''BDR regimen'''
| style="padding: 5px 5px; background: #F5F5F5;" |
*Bortezomib
*Dexamethasone
*Rituximab
| style="padding: 5px 5px; background: #F5F5F5;" |
*Peripheral Neuropathy - reversible in 61% of patients
|-
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |
'''DRC regimen'''
| style="padding: 5px 5px; background: #F5F5F5;" |
*Dexamethasone
*Rituximab
*Cyclophosphamide
| style="padding: 5px 5px; background: #F5F5F5;" |
*Neutropenia
|-
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |
'''CR regimen'''
| style="padding: 5px 5px; background: #F5F5F5;" |
*Cladribine
*Rituximab
| style="padding: 5px 5px; background: #F5F5F5;" |
*Anemia
*Neurological symptoms
*Symptomatic cryoglobulinemia
*Thrombocytopenia
|-
|}
 
 
 
==References==
{{reflist|2}}
 
{{WH}}
{{WS}}
 
 
[[Category:Disease]]
[[Category:Blood]]
[[Category:Hematology]]

Revision as of 16:27, 23 November 2015

CT of SCLC showing extensive stage-Venous phase